[A26-14] Tirzepatide (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2026
Project no.:
A26-14
Commission:
Commission awarded on 24.02.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Children and adolescents aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient blood glucose control with their previous drug therapy in addition to diet and exercise
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-14
| Project no. | Title | Status |
|---|---|---|
| A23-112 | Tirzepatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V | Commission completed |